CA2836277A1 - Pharmaceutical compositions and methods for treating cancer - Google Patents

Pharmaceutical compositions and methods for treating cancer Download PDF

Info

Publication number
CA2836277A1
CA2836277A1 CA2836277A CA2836277A CA2836277A1 CA 2836277 A1 CA2836277 A1 CA 2836277A1 CA 2836277 A CA2836277 A CA 2836277A CA 2836277 A CA2836277 A CA 2836277A CA 2836277 A1 CA2836277 A1 CA 2836277A1
Authority
CA
Canada
Prior art keywords
effective amount
therapeutically effective
dose level
cancer
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2836277A
Other languages
English (en)
French (fr)
Inventor
Oliver Rosen
Iain James WEBB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2836277A1 publication Critical patent/CA2836277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2836277A 2011-05-17 2012-05-17 Pharmaceutical compositions and methods for treating cancer Abandoned CA2836277A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US61/486,851 2011-05-17
US201161538246P 2011-09-23 2011-09-23
US61/538,246 2011-09-23
PCT/US2012/038292 WO2012158884A1 (en) 2011-05-17 2012-05-17 Pharmaceutical compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA2836277A1 true CA2836277A1 (en) 2012-11-22

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836277A Abandoned CA2836277A1 (en) 2011-05-17 2012-05-17 Pharmaceutical compositions and methods for treating cancer

Country Status (7)

Country Link
EP (1) EP2709614A4 (zh)
JP (1) JP2014513730A (zh)
AR (1) AR086444A1 (zh)
CA (1) CA2836277A1 (zh)
TW (1) TW201309291A (zh)
UY (1) UY34078A (zh)
WO (1) WO2012158884A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CA2902335C (en) * 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
JP5350217B2 (ja) * 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
PE20130603A1 (es) * 2007-10-29 2013-05-30 Takeda Pharmaceutical Composicion farmaceutica que contiene un inhibidor de esteroide c17,20 liasa

Also Published As

Publication number Publication date
UY34078A (es) 2012-11-30
AR086444A1 (es) 2013-12-11
EP2709614A4 (en) 2015-04-15
WO2012158884A1 (en) 2012-11-22
JP2014513730A (ja) 2014-06-05
EP2709614A1 (en) 2014-03-26
TW201309291A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
CA2836277A1 (en) Pharmaceutical compositions and methods for treating cancer
JP6445123B2 (ja) 癌を治療するための方法及び組成物
US10702540B2 (en) Methods and compositions for treating cancer
US20110319369A1 (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
CN118215466A (zh) 口服阿比特龙制剂
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
WO2023167783A1 (en) Abiraterone decanoate prodrugs and use in therapy
TW201532613A (zh) 用於贅瘤（ｎｅｏｐｌａｓｉａ）治療之組合療法

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160519